Overview

Pembrolizumab After SBRT Versus Pembrolizumab Alone in Advanced NSCLC

Status:
Completed
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
To evaluate the increase in Overall Response Rate (ORR) in the pembrolizumab alone arm compared to the pembrolizumab after SBRT arm at 12 weeks
Phase:
Phase 2
Details
Lead Sponsor:
The Netherlands Cancer Institute
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Pembrolizumab